I-SPY2 Participant Information
Widely hailed as the future of phase II drug development, the adaptive I-SPY 2 platform trial has set a new benchmark for efficiency, through innovation in trial design and clinical operations.
Please see the attached message regarding the COVID-19 pandemic for patients enrolled in the I-SPY2 trial.
If you have any questions or concerns, please contact your clinical coordinator.
Dr. Laura Esserman discusses "How to think about your cancer care in the time of COVID-19" for Time magazine.
view video and article
Learn about the I-SPY2 Trial from our subject matter experts